No products in the cart.
Blog
What to know about retatrutide: An investigational triple hormone receptor agonist
01
Jun
Jun
What to Know About Synedica Retatrutide
The world’s most advanced triple hormone receptor agonist — everything patients, researchers, and weight-management professionals need to know in one place.
What Is Synedica Retatrutide?
Synedica Retatrutide is an investigational prefilled injection pen kit containing retatrutide — a first-in-class triple hormone receptor agonist developed for advanced weight management and metabolic health. Originally investigated by Eli Lilly, retatrutide simultaneously targets three incretin receptors in the body: GLP-1, GIP, and glucagon — a mechanism that sets it apart from every other weight-loss treatment currently available.
The Synedica Retatrutide 40 mg pen kit is designed for patients who have already worked through semaglutide and tirzepatide-based protocols, or for those whose healthcare providers recommend starting with the most comprehensive receptor approach from the outset. Early trial data — including the pivotal 2026 Phase 3 TRIUMPH-1 results — have generated enormous clinical interest.
⚕️ Important: Retatrutide is currently investigational. Always consult a qualified healthcare professional before starting any peptide or injectable weight-management programme.
How Does Synedica Retatrutide Work?
To understand what makes retatrutide distinctive, it helps to understand the receptors it targets:
GLP-1 (Glucagon-Like Peptide-1)
GLP-1 slows gastric emptying, reduces appetite by signalling satiety to the brain, and stimulates insulin secretion in a glucose-dependent manner. This is the same receptor targeted by semaglutide (Ozempic/Wegovy) and one of the two targeted by tirzepatide (Mounjaro/Zepbound).
GIP (Glucose-Dependent Insulinotropic Polypeptide)
GIP works synergistically with GLP-1 to enhance insulin release and appears to play a role in regulating fat metabolism and energy expenditure. Tirzepatide was the first commercially approved agent to combine GLP-1 and GIP activation.
Glucagon Receptor
Glucagon activation increases energy expenditure and promotes fat breakdown (lipolysis), particularly in the liver. Adding glucagon agonism to the GLP-1/GIP combination is what separates retatrutide from all previous incretin therapies. By acting on all three pathways simultaneously, Synedica Retatrutide delivers appetite suppression, glucose optimisation, and enhanced fat metabolism in a single weekly injection.
🔬 Think of it this way: semaglutide turns one dial, tirzepatide turns two, and retatrutide turns all three. Each additional receptor adds a layer of metabolic effect, which is reflected in the growing body of clinical evidence.
2025–2026 Phase 3 Clinical Trial Results
Retatrutide has generated some of the most impressive efficacy data ever seen in obesity research. Here are the headline results from the major Phase 3 trials:
28.3%
Average body weight lost at 80 weeks (TRIUMPH-1, 12 mg)
70.3 lbs
Average weight lost in TRIUMPH-1 at the 12 mg dose
45.3%
Participants achieving ≥30% weight loss (TRIUMPH-1)
2.0%
Average A1C reduction in TRANSCEND-T2D-1 (type 2 diabetes trial)
TRIUMPH-1 (Pivotal Obesity Trial, May 2026)
The TRIUMPH-1 Phase 3 trial — results announced in May 2026 — evaluated retatrutide in adults with obesity or overweight and at least one weight-related comorbidity. At 80 weeks, participants on the 12 mg dose lost an average of 70.3 lbs (28.3% of body weight). Critically, 45.3% of participants achieved ≥30% weight loss — a threshold rarely seen in any pharmacological intervention. All doses (4 mg, 9 mg, 12 mg) met the primary and all key secondary endpoints. (Source: Lilly PR, 2026)
TRIUMPH-4 (Osteoarthritis, December 2025)
TRIUMPH-4 evaluated retatrutide in patients with obesity and knee osteoarthritis. The 12 mg dose delivered an average weight loss of 71.2 lbs alongside substantial, clinically meaningful reductions in osteoarthritis pain and improvements in physical function — suggesting retatrutide may benefit patients who have weight-related comorbidities beyond metabolic disease. (Source: Lilly Investor Relations, 2025)
TRANSCEND-T2D-1 (Type 2 Diabetes, March 2026)
In adults with type 2 diabetes managed on diet and exercise alone, retatrutide met all primary and key secondary endpoints, delivering A1C reductions of up to 2.0 percentage points at 40 weeks. This positions retatrutide as a potentially meaningful advance for patients where glucose control and weight management are both priorities. (Source: Lilly PR, 2026)
MASLD (Liver Fat) Sub-study (Nature Medicine, 2024)
A Phase 2a sub-study published in Nature Medicine demonstrated that retatrutide reduced liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). At the 12 mg dose, 86% of participants achieved normal liver fat levels (<5%) at 24 weeks, compared to 0% on placebo. (Source: Nature Medicine, 2024)
Retatrutide vs Semaglutide vs Tirzepatide
Choosing the right GLP-based treatment depends on your history, tolerance, and goals. Here’s how the three main options compare:
| Feature | Semaglutide | Tirzepatide | Retatrutide ✦ |
|---|---|---|---|
| Receptors targeted | 1 (GLP-1) | 2 (GLP-1 + GIP) | 3 (GLP-1 + GIP + glucagon) |
| Avg. weight loss (Phase 3) | ~15% | ~21–22% | ~24–28% |
| Dosing frequency | Once weekly | Once weekly | Once weekly |
| Also improves liver fat | Modest | Yes | Significant (86% normalisation at 12 mg) |
| Best for | First-line users | After semaglutide tolerance | After tirzepatide tolerance / advanced users |
| Available at Synedica | Yes → | Yes → | Yes → |
The general clinical guidance is: start with semaglutide → progress to tirzepatide if needed → advance to retatrutide if tolerance develops at higher tirzepatide doses. Retatrutide’s three-receptor activation makes it particularly effective for patients whose bodies have adapted to single or dual agonist therapies.
Synedica Retatrutide Dosage Guide
The Synedica Retatrutide 40 mg pen is engineered to support a careful, step-wise dose escalation protocol — the same approach used in Phase 3 trials to minimise GI side effects while maximising efficacy. Each pen can be delivered across four full 10 mg doses, or in increments of 2.5 mg, 5 mg, 7.5 mg, or 10 mg.
1
Weeks 1–4 → 2.5 mg once weekly
The initiation phase. Allows the body to adapt to the triple receptor stimulation with minimal GI disruption.
2
Weeks 5–8 → 5 mg once weekly
The first escalation. Most users notice increasing appetite suppression and satiety signals at this dose.
3
Week 9+ → 7.5 mg or 10 mg (if needed)
Further escalation is optional and should only be made with guidance from a healthcare provider. Most users achieve meaningful results at 5–7.5 mg.
📦 The Synedica Retatrutide 40 mg pen will last the average new user approximately 12 weeks at the standard escalation protocol, and includes 12 disposable 32g 4mm needles and a full instruction booklet.
Side Effects & Safety
Retatrutide’s side effect profile is consistent with other incretin-based therapies. The most important thing to know: most side effects are gastrointestinal, mild, and occur primarily during dose escalation — which is exactly why the gradual dosing protocol exists.
Common side effects reported in Phase 3 trials
Nausea (most common, 38–43% at higher doses)
Diarrhea (33–35% at higher doses)
Vomiting
Constipation
Decreased appetite (expected therapeutic effect)
Dysesthesia (mild, 2–4%)
⚠️ Always read the enclosed instruction booklet in full before use. For a complete list of common and uncommon side effects, refer to the booklet included with your Synedica pen kit, or speak with your prescribing physician. Do not self-prescribe without professional oversight.
Importantly, side effects in Phase 3 trials rarely led to discontinuation. The step-wise dose escalation protocol used with Synedica Retatrutide is specifically designed to reduce GI burden during the body’s adaptation period.
What’s Inside the Synedica Retatrutide 40 mg Pen Kit?
💉
Synedica Retatrutide 40 mg Injection Pen Kit
The complete all-in-one kit for your retatrutide protocol. Everything arrives ready to use, with a clear dosing guide to walk you through each step.
Each kit includes:
- 1 × 40 mg Retatrutide prefilled injection pen (4 full 10 mg doses or increments of 2.5–10 mg)
- 12 × disposable 32g 4mm needles
- 1 × full instruction booklet with dosage protocol, side effect information, and storage guidance
Note: Due to global demand, Synedica currently uses multiple production facilities. Two pen designs are in circulation — both designs contain exactly the same formulation and meet the same quality standard. Always purchase directly from synedica-uk.shop to ensure product authenticity.
⚠️ Counterfeit Warning: A factory in China has been producing and shipping dangerous counterfeit Synedica Retatrutide, Tirzepatide and NAD+ & B12 pens worldwide. Only purchase from authorised Synedica sources. If your pen does not match the verified Synedica design, do not use it.
Who Should Consider Synedica Retatrutide?
Retatrutide is currently most relevant for:
- Individuals who have used semaglutide and tirzepatide and developed a tolerance at higher doses
- Patients seeking the most comprehensive receptor coverage available in a once-weekly injectable
- Those with obesity and related comorbidities including type 2 diabetes, knee osteoarthritis, elevated liver fat (MASLD), or obstructive sleep apnoea
- Wholesale buyers, clinics, and research facilities — see Synedica’s wholesale programme
All new users without prior GLP-1 experience should always start with semaglutide, then if necessary progress to tirzepatide, and then to retatrutide. This stepwise approach allows the body to adapt progressively to receptor agonism.
Frequently Asked Questions
What is the Synedica Retatrutide Injection Pen Kit?
The Synedica Retatrutide 40 mg Injection Pen Kit is a prefilled, all-in-one weekly injection system containing retatrutide — an investigational triple hormone receptor agonist. It suppresses appetite by simultaneously mimicking GLP-1, GIP and glucagon — three natural hormones that signal satiety, optimise glucose levels, and drive fat metabolism. The kit lasts the average new user approximately 12 weeks.
Should I start with semaglutide, tirzepatide, or retatrutide?
Clinical guidance is clear: all new GLP-1 users should start with semaglutide. If a tolerance develops at higher semaglutide doses, tirzepatide (which adds GIP receptor agonism) is the next step. If tolerance develops with tirzepatide at its higher doses, retatrutide — which adds the glucagon receptor — is the logical progression. View all three options at Synedica.
What are the key benefits of the Synedica Retatrutide Pen Kit?
By activating three metabolic receptor pathways simultaneously, users experience sustained appetite suppression throughout the day — enabling significant, lasting fat loss without the constant hunger typical of traditional calorie-restricted diets. Phase 3 data shows weight reductions of up to 28.3% at 80 weeks.
Where can I purchase a genuine Synedica Retatrutide Pen Kit?
Synedica Retatrutide Pen Kits are available directly at synedica-uk.shop. Wholesale and clinic purchasing is available via the Synedica wholesale programme. Always buy from the official source to avoid counterfeit products.
What is the difference between the two pen designs?
Due to worldwide demand, Synedica currently operates multiple production facilities, resulting in two pen designs. Both contain the same 40 mg retatrutide formulation and meet the same quality standard. The design of the pen does not affect the product.
Why Patients Choose Synedica
Transparent pricing
No hidden fees, no guesswork. Single pen to wholesale quantities, all clearly priced.
Free shipping on all orders
Every order ships free with fast, discreet delivery. Tracked and insured.
4.9 rating across 287 reviews
Trusted by patients, clinics and wholesale partners across the UK and Europe.
Wholesale partner support
Friendly, experienced wholesale support for clinics and healthcare providers who really care.
Ready to Begin?
Browse the full Synedica range — from semaglutide and tirzepatide to retatrutide — or enquire about wholesale pricing for your clinic.
External Sources & References
- Eli Lilly and Company. TRIUMPH-1 Phase 3 Pivotal Obesity Trial Topline Results. May 2026. prnewswire.com
- Eli Lilly and Company. TRIUMPH-4 Phase 3 Osteoarthritis Trial Results. December 2025. investor.lilly.com
- Eli Lilly and Company. TRANSCEND-T2D-1 Phase 3 Type 2 Diabetes Trial Results. March 2026. prnewswire.com
- Nature Medicine. Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial. 2024. nature.com
- NCT05869903 — TRIUMPH-4 Clinical Trial. ClinicalTrials.gov. clinicaltrials.gov
Where to Buy Synedica Retatrutide 40mg Online
If you are searching for where to buy Synedica Retatrutide 40mg online, it is important to choose a trusted and reliable source that guarantees authenticity, quality, and secure delivery. Synedica Retatrutide 40mg has become a highly searched peptide product among individuals looking for premium peptide solutions and dependable online ordering experiences. As demand continues to grow, buyers should always prioritize purchasing from an official and verified supplier.
